Somewhat similar to the Lumina trial, in this study, postmenopausal woman aged 50–69 with T1N0 ER+HER2- breast cancer treated with breast-conserving surgery and an RS ≤ 18 will receive adjuvant endocrine therapy alone and radiation therapy will be omitted. This evidence concerns the gene ERBB2 and breast carcinoma.